Fresenius Medical Care AG & Co. KGaA ADR (FMS)
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take hold.
CVS vs. FMS: Which Healthcare Services Stock Has More Upside?
CVS outpaces FMS in share gains and valuation appeal, with stronger earnings momentum and expanding health services driving its edge.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity right now?
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division Graham Doyle - UBS Investment Bank, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Hugo Solvet - BNP Paribas Exane, Research Division James Alexander Stewart Vane- Tempest - Jefferies LLC, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Veronika Dubajova - Citigroup Inc., Research Division a divi - Unidentified Company ion - Unidentified Company f S& - Global Inc. All Rights reserved. Operator Ladies and gentlemen, welcome to the Report on Second Quarter 2025 Conference Call.
Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
Fresenius (FMS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why Fresenius (FMS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Fresenius Medical Stock?
Investors need to pay close attention to FMS stock based on the movements in the options market lately.
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
